The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: Global vaccine development efforts have been accelerated in response to the devastating coronavirus disease 2019 (COVID-19) pandemic. We evaluated the impact of a 2-dose COVID-19 vaccination campaign on reducing incidence, hospitalizations, and deaths in the United States.
METHODS: We developed an agent-based model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and parameterized it with US demographics and age-specific COVID-19 outcomes. Healthcare workers and high-risk individuals were prioritized for vaccination, whereas children under 18 years of age were not vaccinated. We considered a vaccine efficacy of 95% against disease following 2 doses administered 21 days apart achieving 40% vaccine coverage of the overall population within 284 days. We varied vaccine efficacy against infection and specified 10% preexisting population immunity for the base-case scenario. The model was calibrated to an effective reproduction number of 1.2, accounting for current nonpharmaceutical interventions in the United States.
RESULTS: Vaccination reduced the overall attack rate to 4.6% (95% credible interval [CrI]: 4.3%-5.0%) from 9.0% (95% CrI: 8.4%-9.4%) without vaccination, over 300 days. The highest relative reduction (54%-62%) was observed among individuals aged 65 and older. Vaccination markedly reduced adverse outcomes, with non-intensive care unit (ICU) hospitalizations, ICU hospitalizations, and deaths decreasing by 63.5% (95% CrI: 60.3%-66.7%), 65.6% (95% CrI: 62.2%-68.6%), and 69.3% (95% CrI: 65.5%-73.1%), respectively, across the same period.
CONCLUSIONS: Our results indicate that vaccination can have a substantial impact on mitigating COVID-19 outbreaks, even with limited protection against infection. However, continued compliance with nonpharmaceutical interventions is essential to achieve this impact.
Errataetall: | |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
---|---|
Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 12 vom: 16. Dez., Seite 2257-2264 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Moghadas, Seyed M [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
Date Completed 22.12.2021 Date Revised 08.11.2023 published: Print UpdateOf: medRxiv. 2021 Jan 02;:. - PMID 33269359 Citation Status MEDLINE |
---|
doi: |
10.1093/cid/ciab079 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM320766780 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM320766780 | ||
003 | DE-627 | ||
005 | 20231225174312.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/cid/ciab079 |2 doi | |
028 | 5 | 2 | |a pubmed24n1069.xml |
035 | |a (DE-627)NLM320766780 | ||
035 | |a (NLM)33515252 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Moghadas, Seyed M |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.12.2021 | ||
500 | |a Date Revised 08.11.2023 | ||
500 | |a published: Print | ||
500 | |a UpdateOf: medRxiv. 2021 Jan 02;:. - PMID 33269359 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
520 | |a BACKGROUND: Global vaccine development efforts have been accelerated in response to the devastating coronavirus disease 2019 (COVID-19) pandemic. We evaluated the impact of a 2-dose COVID-19 vaccination campaign on reducing incidence, hospitalizations, and deaths in the United States | ||
520 | |a METHODS: We developed an agent-based model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and parameterized it with US demographics and age-specific COVID-19 outcomes. Healthcare workers and high-risk individuals were prioritized for vaccination, whereas children under 18 years of age were not vaccinated. We considered a vaccine efficacy of 95% against disease following 2 doses administered 21 days apart achieving 40% vaccine coverage of the overall population within 284 days. We varied vaccine efficacy against infection and specified 10% preexisting population immunity for the base-case scenario. The model was calibrated to an effective reproduction number of 1.2, accounting for current nonpharmaceutical interventions in the United States | ||
520 | |a RESULTS: Vaccination reduced the overall attack rate to 4.6% (95% credible interval [CrI]: 4.3%-5.0%) from 9.0% (95% CrI: 8.4%-9.4%) without vaccination, over 300 days. The highest relative reduction (54%-62%) was observed among individuals aged 65 and older. Vaccination markedly reduced adverse outcomes, with non-intensive care unit (ICU) hospitalizations, ICU hospitalizations, and deaths decreasing by 63.5% (95% CrI: 60.3%-66.7%), 65.6% (95% CrI: 62.2%-68.6%), and 69.3% (95% CrI: 65.5%-73.1%), respectively, across the same period | ||
520 | |a CONCLUSIONS: Our results indicate that vaccination can have a substantial impact on mitigating COVID-19 outbreaks, even with limited protection against infection. However, continued compliance with nonpharmaceutical interventions is essential to achieve this impact | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a United States | |
650 | 4 | |a outbreak simulation | |
650 | 4 | |a pandemic | |
650 | 4 | |a vaccines | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
700 | 1 | |a Vilches, Thomas N |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Kevin |e verfasserin |4 aut | |
700 | 1 | |a Wells, Chad R |e verfasserin |4 aut | |
700 | 1 | |a Shoukat, Affan |e verfasserin |4 aut | |
700 | 1 | |a Singer, Burton H |e verfasserin |4 aut | |
700 | 1 | |a Meyers, Lauren Ancel |e verfasserin |4 aut | |
700 | 1 | |a Neuzil, Kathleen M |e verfasserin |4 aut | |
700 | 1 | |a Langley, Joanne M |e verfasserin |4 aut | |
700 | 1 | |a Fitzpatrick, Meagan C |e verfasserin |4 aut | |
700 | 1 | |a Galvani, Alison P |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 12 vom: 16. Dez., Seite 2257-2264 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
773 | 1 | 8 | |g volume:73 |g year:2021 |g number:12 |g day:16 |g month:12 |g pages:2257-2264 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciab079 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 73 |j 2021 |e 12 |b 16 |c 12 |h 2257-2264 |